Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS)

Analysts have been eager to weigh in on the Conglomerates sector with new ratings on Norfolk Southern (NSC – Research Report), IDEX (IEX – Research Report) and Fortune Brands (FBHS – Research Report). Norfolk Southern (NSC) RBC Capital analyst Walter Spracklin maintained a Sell rating on Norfolk Southern on July 28 and set a price target of $264.00. The company's shares closed last Friday at $257.83. According to TipRanks.com, Spracklin is a 5-star analyst with an average return of 21.4% and a 71.3% success rate. Spracklin covers the Industrial Goods sector, focusing on stocks such as Andlauer Healthcare Group, GFL Environmental, and TFI International. Currently, the analyst consensus on Norfolk Southern is a Moderate Buy with an average price target of $285.58. See today’s analyst top recommended stocks >> IDEX (IEX) RBC Capital analyst Deane Dray maintained a Buy rating on IDEX on July 28 and set a price target of $252.00. The company's shares closed last Friday at $226.69, close to its 52-week high of $235.76. According to TipRanks.com, Dray is a 5-star analyst with an average return of 11.7% and a 61.3% success rate. Dray covers the Industrial Goods sector, focusing on stocks such as Atkore International Group, Emerson Electric Company, and Honeywell International. IDEX has an analyst consensus of Strong Buy, with a price target consensus of $253.33, implying a 13.5% upside from current levels. In a report issued on July 29, Rosenblatt Securities also assigned a Buy rating to the stock with a $255.00 price target. Fortune Brands (FBHS) RBC Capital analyst Michael Dahl maintained a Hold rating on Fortune Brands on July 28 and set a price target of $114.00. The company's shares closed last Friday at $97.47. According to TipRanks.com, Dahl is a 4-star analyst with an average return of 6.7% and a 55.4% success rate. Dahl covers the Consumer Goods sector, focusing on stocks such as Skyline Champion, Taylor Morrison, and Toll Brothers. Fortune Brands has an analyst consensus of Hold, with a price target consensus of $109.00, representing a 12.7% upside. In a report issued on July 15, Wells Fargo also initiated coverage with a Hold rating on the stock with a $105.00 price target. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on NSC: Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA) Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT) Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF) Barclays Remains a Sell on Moneygram International (MGI) BJ’s Restaurants (BJRI) Gets a Sell Rating from Barclays The post Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS) appeared first on TipRanks Financial Blog.

Analysts have been eager to weigh in on the Conglomerates sector with new ratings on Norfolk Southern (NSC – Research Report), IDEX (IEX – Research Report) and Fortune Brands (FBHS – Research Report).

Norfolk Southern (NSC)

RBC Capital analyst Walter Spracklin maintained a Sell rating on Norfolk Southern on July 28 and set a price target of $264.00. The company's shares closed last Friday at $257.83.

According to TipRanks.com, Spracklin is a 5-star analyst with an average return of 21.4% and a 71.3% success rate. Spracklin covers the Industrial Goods sector, focusing on stocks such as Andlauer Healthcare Group, GFL Environmental, and TFI International.

Currently, the analyst consensus on Norfolk Southern is a Moderate Buy with an average price target of $285.58.

IDEX (IEX)

RBC Capital analyst Deane Dray maintained a Buy rating on IDEX on July 28 and set a price target of $252.00. The company's shares closed last Friday at $226.69, close to its 52-week high of $235.76.

According to TipRanks.com, Dray is a 5-star analyst with an average return of 11.7% and a 61.3% success rate. Dray covers the Industrial Goods sector, focusing on stocks such as Atkore International Group, Emerson Electric Company, and Honeywell International.

IDEX has an analyst consensus of Strong Buy, with a price target consensus of $253.33, implying a 13.5% upside from current levels. In a report issued on July 29, Rosenblatt Securities also assigned a Buy rating to the stock with a $255.00 price target.

Fortune Brands (FBHS)

RBC Capital analyst Michael Dahl maintained a Hold rating on Fortune Brands on July 28 and set a price target of $114.00. The company's shares closed last Friday at $97.47.

According to TipRanks.com, Dahl is a 4-star analyst with an average return of 6.7% and a 55.4% success rate. Dahl covers the Consumer Goods sector, focusing on stocks such as Skyline Champion, Taylor Morrison, and Toll Brothers.

Fortune Brands has an analyst consensus of Hold, with a price target consensus of $109.00, representing a 12.7% upside. In a report issued on July 15, Wells Fargo also initiated coverage with a Hold rating on the stock with a $105.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on NSC:

  • Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA)
  • Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT)
  • Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF)
  • Barclays Remains a Sell on Moneygram International (MGI)
  • BJ’s Restaurants (BJRI) Gets a Sell Rating from Barclays

The post Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP)

Analysts fell to the sidelines weighing in on Seagen (SGEN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Merck & Company (MRK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Seagen (SGEN) In a report issued on July 29, Kennen MacKay from RBC Capital maintained a Hold rating on Seagen, with a price target of $148.00. The company's shares closed last Friday at $153.39. According to TipRanks.com, MacKay is a 4-star analyst with an average return of 12.9% and a 56.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Acceleron Pharma, and Agios Pharma. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seagen with a $187.00 average price target, which is a 23.0% upside from current levels. In a report issued on July 16, Morgan Stanley also maintained a Hold rating on the stock with a $167.00 price target. See today’s analyst top recommended stocks >> Crispr Therapeutics AG (CRSP) RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG on July 30 and set a price target of $117.00. The company's shares closed last Friday at $121.02. According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 31.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Intellia Therapeutics. Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $163.22, representing a 33.3% upside. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $139.00 price target. Merck & Company (MRK) In a report issued on July 29, Daniel Busby from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $80.00. The company's shares closed last Friday at $76.87. According to TipRanks.com, Busby is a 1-star analyst with an average return of -6.1% and a 33.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals. Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $93.57. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Read More on SGEN: Wall Street Analysts Are Bullish on Top Technology Picks Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS) Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA) Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT) Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF) The post Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP) appeared first on TipRanks Financial Blog.

Analysts fell to the sidelines weighing in on Seagen (SGEN – Research Report), Crispr Therapeutics AG (CRSP – Research Report) and Merck & Company (MRK – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.

Seagen (SGEN)

In a report issued on July 29, Kennen MacKay from RBC Capital maintained a Hold rating on Seagen, with a price target of $148.00. The company's shares closed last Friday at $153.39.

According to TipRanks.com, MacKay is a 4-star analyst with an average return of 12.9% and a 56.3% success rate. MacKay covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Acceleron Pharma, and Agios Pharma.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seagen with a $187.00 average price target, which is a 23.0% upside from current levels. In a report issued on July 16, Morgan Stanley also maintained a Hold rating on the stock with a $167.00 price target.

Crispr Therapeutics AG (CRSP)

RBC Capital analyst Luca Issi maintained a Hold rating on Crispr Therapeutics AG on July 30 and set a price target of $117.00. The company's shares closed last Friday at $121.02.

According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 31.3% success rate. Issi covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Adverum Biotechnologies, and Intellia Therapeutics.

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $163.22, representing a 33.3% upside. In a report issued on July 30, Stifel Nicolaus also maintained a Hold rating on the stock with a $139.00 price target.

Merck & Company (MRK)

In a report issued on July 29, Daniel Busby from RBC Capital maintained a Hold rating on Merck & Company, with a price target of $80.00. The company's shares closed last Friday at $76.87.

According to TipRanks.com, Busby is a 1-star analyst with an average return of -6.1% and a 33.3% success rate. Busby covers the Healthcare sector, focusing on stocks such as Osmotica Pharmaceuticals, Verrica Pharmaceuticals, and Pacira Pharmaceuticals.

Merck & Company has an analyst consensus of Moderate Buy, with a price target consensus of $93.57.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on SGEN:

  • Wall Street Analysts Are Bullish on Top Technology Picks
  • Analysts Conflicted on These Conglomerates Names: Norfolk Southern (NSC), IDEX (IEX) and Fortune Brands (FBHS)
  • Analysts Offer Insights on Materials Companies: Sherwin-Williams Company (SHW), West Fraser Timber Co (WFG) and Enviva (EVA)
  • Analysts Offer Insights on Financial Companies: S&P Global (SPGI), Mastercard (MA) and Camden Property (CPT)
  • Analysts Offer Insights on Consumer Goods Companies: Shopify (SHOP), Procter & Gamble (PG) and Nestlé SA (OtherNSRGF)

The post Analysts Are Neutral on These Healthcare Stocks: Seagen (SGEN), Crispr Therapeutics AG (CRSP) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.